Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SASHA COURTNEY DAVIS

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1194019075
CMS profile
2378874
Location
TYLER, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$209.43

5 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $209.43 5

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
Celgene Corporation $96.24 1
Novocure Inc. $60.43 1
Karyopharm Therapeutics Inc. $18.81 1
E.R. Squibb & Sons, L.L.C. $17.62 1
AbbVie Inc. $16.33 1

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SASHA COURTNEY DAVIS

NPI 1194019075 · CMS profile ID 2378874

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

TYLER, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1194019075?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SASHA COURTNEY DAVIS, NPI 1194019075, CMS profile ID 2378874. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1194019075?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). SASHA COURTNEY DAVIS, NPI 1194019075, CMS profile ID 2378874. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1194019075?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
SASHA COURTNEY DAVIS, NPI 1194019075, CMS profile ID 2378874, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1194019075?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

5 matching records · $209.43 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 5 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–5 of 5.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $16.3311/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722144487 CMS
Novocure Inc. $60.4309/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 740699187 CMS
E.R. Squibb & Sons, L.L.C. $17.6208/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727787363 CMS
Karyopharm Therapeutics Inc. $18.8108/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751735349 CMS
Celgene Corporation $96.2402/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727787383 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $388.85 10
PY2020 $209.43 5
PY2021 $358.15 15
PY2022 $556.52 18
PY2023 $1,071.10 29
PY2024 $1,344.13 48
PY2025 $747.53 34

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $91,150.24 16
PY2024 Principal investigator $102,318.97 23
PY2023 Principal investigator $167,396.92 32
PY2022 Principal investigator $244,503.39 39
PY2021 Principal investigator $409,588.59 46
PY2020 Principal investigator $357,909.58 144
PY2019 Principal investigator $105,582.24 109

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

46 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme Corporation $39,090.36 12/31/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2 Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 848747845
Principal investigator 1 Merck Sharp & Dohme Corporation $17,190.45 12/31/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2 Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 848748617
Principal investigator 1 PFIZER INC. $500.00 12/21/2021 Non-covered Recipient Entity
US Oncology LLC
POLARIS PALBOCICLIB IN HORMONE RECEPTOR POSITIVE ADVANCED BREAST CANCER A PROSPECTIVE MULTICENTER NONINTERVENTIONAL STUDY No dispute reported 06/30/2026 832563741
Principal investigator 1 Merck Sharp & Dohme Corporation $6,718.00 12/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2 Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 848758573
Principal investigator 1 Novartis Pharmaceuticals Corporation $40,881.25 12/09/2021 Non-covered Recipient Entity
US ONCOLOGY P A
EPIK-B4: A PHASE II, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DAPAGLIFLOZIN + METFORMIN XR VERSUS METFORMIN XR DURING TREATMENT WITH ALPELISIB (BYL719) IN COMBINATION WITH FULVESTRANT IN PARTICIPANTS WITH HR+, HER2-, ADVANCED BREAST CANCER WITH A PIK3CA MUTATION FOLLOWING PROGRESSION OFTER ENDOCRINE-BASED THERAPY No dispute reported 06/30/2026 800649339
Principal investigator 1 PFIZER INC. $30,538.26 11/04/2021 Non-covered Recipient Entity
US Oncology LLC
POLARIS PALBOCICLIB IN HORMONE RECEPTOR POSITIVE ADVANCED BREAST CANCER A PROSPECTIVE MULTICENTER NONINTERVENTIONAL STUDY No dispute reported 06/30/2026 832812371
Principal investigator 1 Genentech, Inc. $1,500.00 10/24/2021 Non-covered Recipient Entity
PHYSICIANS RELIANCE NETWORK US ONCOLOGY RESEARCH INC
GDC 9545 VS SINGLE AGENT ENDOCRINE THERAPY OF PHYSICIAN S CHOICE IN HR 2L 3L MBC No dispute reported 06/30/2026 835991019
Principal investigator 1 EMD Serono, Inc. $1,063.00 10/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY P.A.
A Phase II, Multicenter, Open Label Study of Bintrafusp alfa (M7824) Monotherapy in Participants with HMGA2-expressing Triple Negative Breast Cancer No dispute reported 06/30/2026 842914819
Principal investigator 1 Genentech, Inc. $5,100.00 10/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY SOUTHWEST FORT WORTH
GDC 9545 VS SINGLE AGENT ENDOCRINE THERAPY OF PHYSICIAN S CHOICE IN HR 2L 3L MBC No dispute reported 06/30/2026 836026651
Principal investigator 1 Radius Health, Inc. $956.00 10/15/2021 Non-covered Recipient Entity
Texas Oncology, P.A.
Anastrazole (Arimidex), Exemestane, Faslodex (fulvestrant), Letrozole, RAD1901 (Elacestrant) Tablet No dispute reported 06/30/2026 830708487
Principal investigator 1 Gilead Sciences, Inc. $1,250.00 10/13/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Phase III Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) Who Have Failed At Least Two Prior Chemotherapy Regimens No dispute reported 06/30/2026 803531933
Principal investigator 1 Radius Health, Inc. $1,125.00 10/11/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF ELACESTRANT (RAD1901) VERSUS INVESTIGATORS CHOICE OF FULVESTRANT OR AROMATASE INHIBITOR THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER+/HER2- BREAST CANCER No dispute reported 06/30/2026 830711473
Principal investigator 1 Radius Health, Inc. $1,125.00 10/07/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF ELACESTRANT (RAD1901) VERSUS INVESTIGATORS CHOICE OF FULVESTRANT OR AROMATASE INHIBITOR THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER+/HER2- BREAST CANCER No dispute reported 06/30/2026 830711659
Principal investigator 1 Radius Health, Inc. $28,625.00 09/29/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF ELACESTRANT (RAD1901) VERSUS INVESTIGATORS CHOICE OF FULVESTRANT OR AROMATASE INHIBITOR THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER+/HER2- BREAST CANCER No dispute reported 06/30/2026 830711331
Principal investigator 1 Radius Health, Inc. $171.00 08/15/2021 Non-covered Recipient Entity
Texas Oncology, P.A.
Anastrazole (Arimidex), Exemestane, Faslodex (fulvestrant), Letrozole, RAD1901 (Elacestrant) Tablet No dispute reported 06/30/2026 830708357
Principal investigator 1 Radius Health, Inc. $199.98 08/12/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF ELACESTRANT (RAD1901) VERSUS INVESTIGATORS CHOICE OF FULVESTRANT OR AROMATASE INHIBITOR THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER+/HER2- BREAST CANCER No dispute reported 06/30/2026 830711303
Principal investigator 1 PFIZER INC. $1,500.00 08/11/2021 Non-covered Recipient Entity
US Oncology LLC
POLARIS PALBOCICLIB IN HORMONE RECEPTOR POSITIVE ADVANCED BREAST CANCER A PROSPECTIVE MULTICENTER NONINTERVENTIONAL STUDY No dispute reported 06/30/2026 832846373
Principal investigator 1 Radius Health, Inc. $5,381.86 07/19/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF ELACESTRANT (RAD1901) VERSUS INVESTIGATORS CHOICE OF FULVESTRANT OR AROMATASE INHIBITOR THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER+/HER2- BREAST CANCER No dispute reported 06/30/2026 830711339
Principal investigator 1 EMD Serono, Inc. $1,063.00 07/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY P.A.
A Phase II, Multicenter, Open Label Study of Bintrafusp alfa (M7824) Monotherapy in Participants with HMGA2-expressing Triple Negative Breast Cancer No dispute reported 06/30/2026 842932143
Principal investigator 1 Radius Health, Inc. $956.00 07/15/2021 Non-covered Recipient Entity
Texas Oncology, P.A.
Anastrazole (Arimidex), Exemestane, Faslodex (fulvestrant), Letrozole, RAD1901 (Elacestrant) Tablet No dispute reported 06/30/2026 830708404
Principal investigator 1 Gilead Sciences, Inc. $1,250.00 07/13/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Phase III Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) Who Have Failed At Least Two Prior Chemotherapy Regimens No dispute reported 06/30/2026 803531931
Principal investigator 1 Radius Health, Inc. $199.88 06/29/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF ELACESTRANT (RAD1901) VERSUS INVESTIGATORS CHOICE OF FULVESTRANT OR AROMATASE INHIBITOR THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER+/HER2- BREAST CANCER No dispute reported 06/30/2026 830711049
Principal investigator 1 Genentech, Inc. $1,500.00 06/27/2021 Non-covered Recipient Entity
PHYSICIANS RELIANCE NETWORK US ONCOLOGY RESEARCH INC
GDC 9545 VS SINGLE AGENT ENDOCRINE THERAPY OF PHYSICIAN S CHOICE IN HR 2L 3L MBC No dispute reported 06/30/2026 835990739
Principal investigator 1 Radius Health, Inc. $4,018.42 06/24/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF ELACESTRANT (RAD1901) VERSUS INVESTIGATORS CHOICE OF FULVESTRANT OR AROMATASE INHIBITOR THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER+/HER2- BREAST CANCER No dispute reported 06/30/2026 830711103
Principal investigator 1 Radius Health, Inc. $599.64 06/24/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF ELACESTRANT (RAD1901) VERSUS INVESTIGATORS CHOICE OF FULVESTRANT OR AROMATASE INHIBITOR THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER+/HER2- BREAST CANCER No dispute reported 06/30/2026 830711113
Principal investigator 1 Radius Health, Inc. $171.00 06/15/2021 Non-covered Recipient Entity
Texas Oncology, P.A.
RAD1901-308 No dispute reported 06/30/2026 830707659
Principal investigator 1 Radius Health, Inc. $30,246.78 05/03/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF ELACESTRANT (RAD1901) VERSUS INVESTIGATORS CHOICE OF FULVESTRANT OR AROMATASE INHIBITOR THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER+/HER2- BREAST CANCER No dispute reported 06/30/2026 830711075
Principal investigator 1 EMD Serono, Inc. $1,063.00 04/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY P.A.
A Phase II, Multicenter, Open Label Study of Bintrafusp alfa (M7824) Monotherapy in Participants with HMGA2-expressing Triple Negative Breast Cancer No dispute reported 06/30/2026 842932043
Principal investigator 1 Genentech, Inc. $9,350.00 04/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY SOUTHWEST FORT WORTH
GDC 9545 VS SINGLE AGENT ENDOCRINE THERAPY OF PHYSICIAN S CHOICE IN HR 2L 3L MBC No dispute reported 06/30/2026 836026579
Principal investigator 1 Radius Health, Inc. $956.00 04/15/2021 Non-covered Recipient Entity
Texas Oncology, P.A.
RAD1901-308 No dispute reported 06/30/2026 830708233
Principal investigator 1 Gilead Sciences, Inc. $1,250.00 04/13/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Phase III Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) Who Have Failed At Least Two Prior Chemotherapy Regimens No dispute reported 06/30/2026 803531929
Principal investigator 1 Radius Health, Inc. $28,625.00 04/08/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF ELACESTRANT (RAD1901) VERSUS INVESTIGATORS CHOICE OF FULVESTRANT OR AROMATASE INHIBITOR THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER+/HER2- BREAST CANCER No dispute reported 06/30/2026 830711067
Principal investigator 1 Radius Health, Inc. $35,581.80 04/01/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF ELACESTRANT (RAD1901) VERSUS INVESTIGATORS CHOICE OF FULVESTRANT OR AROMATASE INHIBITOR THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER+/HER2- BREAST CANCER No dispute reported 06/30/2026 830711093
Principal investigator 1 Radius Health, Inc. $171.00 03/15/2021 Non-covered Recipient Entity
Texas Oncology, P.A.
RAD1901-308 No dispute reported 06/30/2026 830708109
Principal investigator 1 Radius Health, Inc. $23,851.00 03/11/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF ELACESTRANT (RAD1901) VERSUS INVESTIGATORS CHOICE OF FULVESTRANT OR AROMATASE INHIBITOR THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER+/HER2- BREAST CANCER No dispute reported 06/30/2026 830711039
Principal investigator 1 Radius Health, Inc. $22,014.33 03/08/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF ELACESTRANT (RAD1901) VERSUS INVESTIGATORS CHOICE OF FULVESTRANT OR AROMATASE INHIBITOR THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER+/HER2- BREAST CANCER No dispute reported 06/30/2026 830711029
Principal investigator 1 Radius Health, Inc. $11,195.02 03/04/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF ELACESTRANT (RAD1901) VERSUS INVESTIGATORS CHOICE OF FULVESTRANT OR AROMATASE INHIBITOR THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER+/HER2- BREAST CANCER No dispute reported 06/30/2026 830711001
Principal investigator 1 Genentech, Inc. $9,500.00 02/22/2021 Non-covered Recipient Entity
PHYSICIANS RELIANCE NETWORK US ONCOLOGY RESEARCH INC
GDC 9545 VS SINGLE AGENT ENDOCRINE THERAPY OF PHYSICIAN S CHOICE IN HR 2L 3L MBC No dispute reported 06/30/2026 835990519
Principal investigator 1 Radius Health, Inc. $7,771.56 02/04/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF ELACESTRANT (RAD1901) VERSUS INVESTIGATORS CHOICE OF FULVESTRANT OR AROMATASE INHIBITOR THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER+/HER2- BREAST CANCER No dispute reported 06/30/2026 830711019
Principal investigator 1 Radius Health, Inc. $28,625.00 01/18/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF ELACESTRANT (RAD1901) VERSUS INVESTIGATORS CHOICE OF FULVESTRANT OR AROMATASE INHIBITOR THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER+/HER2- BREAST CANCER No dispute reported 06/30/2026 830711010
Principal investigator 1 Genentech, Inc. $1,275.00 01/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY SOUTHWEST FORT WORTH
PHASE III IN CDK4 6 INHIBITOR EXPERIENCED PIK3CA MUTANT HR HER2 METASTATIC BREAST CANCER No dispute reported 06/30/2026 836026741
Principal investigator 1 Radius Health, Inc. $956.00 01/15/2021 Non-covered Recipient Entity
Texas Oncology, P.A.
RAD1901-308 No dispute reported 06/30/2026 830707949
Principal investigator 1 Radius Health, Inc. $171.00 01/15/2021 Non-covered Recipient Entity
Texas Oncology, P.A.
RAD1901-308 No dispute reported 06/30/2026 830707997
Principal investigator 1 Radius Health, Inc. $171.00 01/15/2021 Non-covered Recipient Entity
Texas Oncology, P.A.
RAD1901-308 No dispute reported 06/30/2026 830708007
Principal investigator 1 Gilead Sciences, Inc. $1,250.00 01/12/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Phase III Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) Who Have Failed At Least Two Prior Chemotherapy Regimens No dispute reported 06/30/2026 803531927
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,892.00 01/06/2021 Non-covered Recipient Entity
US ONCOLOGY P A
A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ALPELISIB (BYL719) IN COMBINATION WITH NAB-PACLITAXEL IN PATIENTS WITH ADVANCED TRIPLE NEGATIVE BREAST CANCER WITH EITHER PHOSPHOINOSITIDE-3-KINASE CATALYTIC SUBUNIT ALPHA (PIK3CA) MUTATION OR PHOSPHATASE AND TENSIN HOMOLOG PROTEIN (PTEN) LOSS WITHOUT PIK3CA MUTATION No dispute reported 06/30/2026 800649315